Tag: Chemotherapy and Cancer Pharmacology

A phase 1 dose‐escalation study of LY3295668 erbumine as monotherapy and in combination with topotecan and cyclophosphamide in children with relapsed/refractory neuroblastoma

This phase 1 study demonstrated that LY3295668 erbumine, a highly selective, orally bioavailable, and reversible Aurora kinase A inhibitor, both as monotherapy and in combination with standard chemotherapy in children with relapsed/refractory neuroblastoma, had a manageable safety profile. Despite robust preclinical data, relatively modest clinical activity (two partial responses and two minor responses with combination… Continue reading A phase 1 dose‐escalation study of LY3295668 erbumine as monotherapy and in combination with topotecan and cyclophosphamide in children with relapsed/refractory neuroblastoma

Comparison of survival outcomes for patients with Lynch vs non‐Lynch syndrome and microsatellite unstable colorectal cancer treated with immunotherapy

Abstract Background Alterations in mismatch repair (MMR) genes like MLH1, MSH2, MSH6, and PMS2 can lead to microsatellite instability–high (MSI-H) tumors. These mutations can be inherited, as in Lynch syndrome (LS), or occur de novo. Although immune checkpoint inhibitors (ICI) improves survival in MSI-H colorectal cancer (CRC) compared to chemotherapy, data comparing outcomes for patients with… Continue reading Comparison of survival outcomes for patients with Lynch vs non‐Lynch syndrome and microsatellite unstable colorectal cancer treated with immunotherapy

Results of Cancer and Leukemia Group B 10102 (Alliance), a Phase 1/2 Study

Abstract Background Acute lymphoblastic leukemia (ALL) in adults is aggressive, with long-term outcomes impacted by treatment resistance and toxicity. CD52 is expressed in most cases of B- and T-lineage ALL. Alemtuzumab, a humanized immunoglobulin G1 monoclonal antibody that targets CD52, was identified as a potential agent to improve treatment efficacy without increasing toxicity. Methods In… Continue reading Results of Cancer and Leukemia Group B 10102 (Alliance), a Phase 1/2 Study

AACR Patient Advocate Forum: Patient-centric Cancer Clinical Trial Design

Before a new treatment becomes available for cancer patients, it must be tested in clinical trials and shown to be both safe for use and effective at treating the disease. But an explosion of new approaches to care, the rise of precision oncology that targets certain tumor mutations rather than broad cancer types, and low rates… Continue reading AACR Patient Advocate Forum: Patient-centric Cancer Clinical Trial Design

Results of Cancer and Leukemia Group B 10102 (Alliance), a Phase 1/2 Study

Abstract Background Acute lymphoblastic leukemia (ALL) in adults is aggressive, with long-term outcomes impacted by treatment resistance and toxicity. CD52 is expressed in most cases of B- and T-lineage ALL. Alemtuzumab, a humanized immunoglobulin G1 monoclonal antibody that targets CD52, was identified as a potential agent to improve treatment efficacy without increasing toxicity. Methods In… Continue reading Results of Cancer and Leukemia Group B 10102 (Alliance), a Phase 1/2 Study

Breakthrough in childhood brain cancer research could heal treatment-resistant tumors, keep them in remission

Research has shown that a potential new targeted therapy for childhood brain cancer is effective in infiltrating and killing tumor cells in preclinical models tested in mice. The novel drug CT-179 was shown to target a specific subset of tumor cells responsible for recurrence and therapy resistance in pediatric brain cancer. The findings could lead… Continue reading Breakthrough in childhood brain cancer research could heal treatment-resistant tumors, keep them in remission